PRF-110's positive preclinical comparison de-risks the program modestly, but the stock remains highly speculative given the $1M market cap and lack of clinical data. Monitor for next steps in development and potential capital raises.
Price Chart
Executive Summary
PRF Technologies announced positive preclinical head-to-head results for PRF-110 vs. ZYNRELEF in a pig incisional pain model, showing comparable analgesic activity over 72 hours with an NSAID-free ropivacaine formulation. The data supports continued development but does not change the company's clinical-stage risk profile.
Key Facts
- PRF-110 showed comparable analgesic activity to ZYNRELEF over 72 hours in a preclinical pig incisional pain model.
- PRF-110 is an NSAID-free, ropivacaine-only extended-release formulation, potentially offering lower cardiac toxicity than bupivacaine.
- The study is preclinical; human clinical trials and regulatory approval remain necessary before commercialization.
Financial Impact
No financial impact quantified; preclinical data does not generate revenue.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- Company has going concern risk and needs additional capital to fund development.
- Regulatory pathway for PRF-110 is uncertain and could face delays or failure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301087 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $0.7400 | awaiting T+60 | — | $0.7321 (−1.07%) |
Oct 23, 2026 4d ago | Press Release | $0.7400 | awaiting T+60 | — | $0.7321 (−1.07%) |
Sep 28, 2026 29d ago | 6-K | $0.9720 | awaiting T+60 | — | $0.7321 (−24.68%) |
Sep 24, 2026 4w ago | SC 13D | $0.9767 | awaiting T+60 | — | $0.7321 (−25.04%) |
Sep 16, 2026 5w ago | 6-K | $1.01 | awaiting T+60 | — | $0.7321 (−27.51%) |
Sep 4, 2026 7w ago | EFFECT | $0.9680 | awaiting T+60 | — | $0.7321 (+24.37%) |
Sep 3, 2026 7w ago | 6-K | $0.9792 | awaiting T+60 | — | $0.7321 (−25.23%) |
Sep 3, 2026 7w ago | Press Release | $0.9792 | awaiting T+60 | — | $0.7321 (−25.23%) |
Jul 27, 2026 13w ago | 6-K | $1.09 $0.7120 | ▼ −34.68% | ▼ −38.38% | $0.7321 (−32.83%) |
Jul 21, 2026 14w ago | 6-K | $1.20 $0.8180 | ▼ −31.83% | ▼ −35.81% | $0.7321 (−38.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers